Journal of Clinical Oncology, Vol 16, 3486-3492, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study

EG Mansour, R Gray, AH Shatila, DC Tormey, MR Cooper, CK Osborne and G Falkson
Case Western Reserve University, Cleveland, OH, USA. emansour@metrohealth.org

PURPOSE: Preliminary analysis showed that adjuvant chemotherapy is effective in improving disease-free survival (DFS) among high-risk breast cancer patients. This report updates the analysis of the high- risk group and reports the results of the low-risk group. METHODS: Patients who had undergone a modified radical mastectomy or a total mastectomy with low-axillary sampling, with negative axillary nodes and either an estrogen receptor-negative (ER-) tumor of any size or an estrogen receptor-positive (ER+) tumor that measured > or = 3 cm (high- risk) were randomized to receive six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone (CMFP) or no further treatment. Patients with ER+ tumors less than 3 cm (low-risk) were monitored without therapy. RESULTS: DFS and overall survival (OS) at 10 years were 73% and 81%, respectively, among patients who received chemotherapy, as compared with 58% and 71% in the observation group (P=.0006 for DFS and P=.02 for OS). Chemotherapy was beneficial for patients with large tumors, both ER+ and ER-, showing a 10-year DFS of 70% versus 51 % (P=.0009) and OS of 75% versus 65% (P=.06). Ten-year survival was 77% among low-risk patients, 85% among premenopausal patients, and 73% in the postmenopausal group. CONCLUSION: The observed 37% reduction in risk of recurrence and 34% reduction in mortality risk at 10 years, associated with a 15.4% absolute benefit in disease-free state and 10.1% in survival, reaffirm the role of adjuvant chemohormonal therapy in the management of high-risk node-negative breast cancer. Tumor size remains a significant prognostic factor associated with recurrence and survival in the low-risk group.

This article has been cited by other articles:

				M. J. Hassett, M. E. Hughes, J. C. Niland, S. B. Edge, R. L. Theriault, Y.-N. Wong, J. Wilson, W. B. Carter, D. W. Blayney, and J. C. Weeks Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer J. Clin. Oncol., December 1, 2008; 26(34): 5553 - 5560. [Abstract] [Full Text] [PDF]

				L. B. Marks, J. Zeng, and L. R. Prosnitz One to Three Versus Four or More Positive Nodes and Postmastectomy Radiotherapy: Time to End the Debate J. Clin. Oncol., May 1, 2008; 26(13): 2075 - 2077. [Full Text] [PDF]

				D. Rayson, D. Chiasson, and R. Dewar Elapsed time from breast cancer detection to first adjuvant therapy in a Canadian province, 1999-2000 Can. Med. Assoc. J., March 16, 2004; 170(6): 957 - 961. [Abstract] [Full Text] [PDF]

				International Breast Cancer Study Group (IBCSG) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial J Natl Cancer Inst, July 17, 2002; 94(14): 1054 - 1065. [Abstract] [Full Text] [PDF]

				A. Paradiso, F. Schittulli, G. Cellamare, A. Mangia, F. Marzullo, V. Lorusso, and M. De Lena Randomized Clinical Trial of Adjuvant Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy for Patients With Fast-Proliferating, Node-Negative Breast Cancer J. Clin. Oncol., October 1, 2001; 19(19): 3929 - 3937. [Abstract] [Full Text]

				P. M. Ravdin, L. A. Siminoff, G. J. Davis, M. B. Mercer, J. Hewlett, N. Gerson, and H. L. Parker Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer J. Clin. Oncol., February 15, 2001; 19(4): 980 - 991. [Abstract] [Full Text] [PDF]

				D. Amadori, O. Nanni, M. Marangolo, P. Pacini, A. Ravaioli, A. Rossi, A. Gambi, G. Catalano, D. Perroni, E. Scarpi, et al. Disease-Free Survival Advantage of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Patients With Node-Negative, Rapidly Proliferating Breast Cancer: A Randomized Multicenter Study J. Clin. Oncol., September 17, 2000; 18(17): 3125 - 3134. [Abstract] [Full Text] [PDF]

				A. C. Wolff and N. E. Davidson Primary Systemic Therapy in Operable Breast Cancer J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569. [Abstract] [Full Text] [PDF]

				J.A. Wils, J.M. Bliss, M. Marty, G. Coombes, C. Fontaine, F. Morvan, T. Olmos, F.R. Perez-Lopez, P. Vassilopoulos, E. Woods, et al. Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group J. Clin. Oncol., July 1, 1999; 17(7): 1988 - 1988. [Abstract] [Full Text] [PDF]